GC Wealth Management RIA LLC Acquires Shares of 29,429 Progyny, Inc. $PGNY

Key Points

• GC Wealth Management RIA LLC acquired 29,429 shares of Progyny, Inc., valued at approximately $647,000, during the second quarter.
• Progyny has received several upgrades from analysts, with price targets ranging from $25.00 to $28.00, and a consensus rating of "Moderate Buy."
• The company's stock has shown fluctuations, with a 12-month low of $13.39 and a high of $26.76, currently trading at $21.52.

GC Wealth Management RIA LLC acquired a new stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 29,429 shares of the company's stock, valued at approximately $647,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC purchased a new position in Progyny in the 1st quarter valued at $354,000. GAMMA Investing LLC lifted its holdings in Progyny by 233.9% in the 1st quarter. GAMMA Investing LLC now owns 5,379 shares of the company's stock valued at $120,000 after purchasing an additional 3,768 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in Progyny by 18.7% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 34,675 shares of the company's stock valued at $775,000 after purchasing an additional 5,459 shares in the last quarter. Voya Investment Management LLC lifted its holdings in Progyny by 258.2% in the 1st quarter. Voya Investment Management LLC now owns 185,495 shares of the company's stock valued at $4,144,000 after purchasing an additional 133,703 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Progyny by 7.5% during the 1st quarter. Millennium Management LLC now owns 1,302,890 shares of the company's stock worth $29,107,000 after acquiring an additional 90,367 shares during the period. Hedge funds and other institutional investors own 94.93% of the company's stock.

Analyst Upgrades and Downgrades

PGNY has been the topic of several analyst reports. JPMorgan Chase & Co. lifted their price target on Progyny from $23.00 to $25.00 and gave the stock a "neutral" rating in a report on Tuesday, August 26th. Leerink Partners upgraded Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price target on the stock in a report on Tuesday, July 8th. Cantor Fitzgerald reiterated an "overweight" rating and set a $28.00 price target (up previously from $26.00) on shares of Progyny in a report on Friday, August 8th. Raymond James Financial set a $28.00 price target on Progyny in a report on Friday, August 8th. Finally, Truist Financial lifted their price target on Progyny from $24.00 to $27.00 and gave the stock a "hold" rating in a report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $25.44.

Progyny Trading Up 0.5%

Shares of PGNY opened at $21.52 on Wednesday. The firm has a market cap of $1.85 billion, a P/E ratio of 36.47, a price-to-earnings-growth ratio of 1.82 and a beta of 1.33. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $26.76. The company's 50-day moving average price is $22.73 and its 200 day moving average price is $22.27.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.23). The company had revenue of $332.87 million during the quarter, compared to analysts' expectations of $315.70 million. Progyny had a net margin of 4.28% and a return on equity of 10.69%. The firm's quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.17 earnings per share. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. Equities research analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current year.

Insider Activity

In other Progyny news, EVP Allison Swartz sold 2,398 shares of Progyny stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $22.96, for a total value of $55,058.08. Following the completion of the transaction, the executive vice president directly owned 79,697 shares of the company's stock, valued at $1,829,843.12. The trade was a 2.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kevin K. Gordon sold 2,500 shares of Progyny stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $22.04, for a total value of $55,100.00. Following the completion of the transaction, the director directly owned 12,501 shares of the company's stock, valued at approximately $275,522.04. This represents a 16.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,895 shares of company stock valued at $179,311. 9.40% of the stock is currently owned by corporate insiders.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.